Jonathan Jay Mazelsky - 14 Nov 2022 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role: President & CEO, Director
Signature: /s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky
Issuer symbol: IDXX
Transactions as of: 14 Nov 2022
Net transactions value: -$3,384,036
Form type: 4
Filing time: 16 Nov 2022, 16:00:11 UTC
Previous filing: 09 Nov 2022
Next filing: 10 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IDXX	Common Stock	Options Exercise	$1,177,876	+18,998	+30%	$62.00^*	81,305	14 Nov 2022	Direct
transaction	IDXX	Common Stock	Sale	$421,240	-972	-1.2%	$433.37	80,333	14 Nov 2022	Direct	F1
transaction	IDXX	Common Stock	Sale	$2,772,760	-6,385	-7.9%	$434.26	73,948	14 Nov 2022	Direct	F2
transaction	IDXX	Common Stock	Sale	$1,106,386	-2,543	-3.4%	$435.07	71,405	14 Nov 2022	Direct	F3
transaction	IDXX	Common Stock	Sale	$261,526	-600	-0.84%	$435.88	70,805	14 Nov 2022	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IDXX	Non-Qualified Stock Option (right-to-buy)	Options Exercise		-18,998	-100%		0	14 Nov 2022	Common Stock	18,998	$62.00	Direct	F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the weighted average price of the shares sold ranging from a low of $432.67 to a high of $433.65 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2	Represents the weighted average price of the shares sold ranging from a low of $433.69 to a high of $434.685 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3	Represents the weighted average price of the shares sold ranging from a low of $434.70 to a high of $435.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F4	Represents the weighted average price of the shares sold ranging from a low of $435.77 to a high of $436.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F5	Grant of option to buy 9,499 shares of Issuer common stock that became exercisable for 8,244 shares in four equal annual installments beginning February 14, 2015 and for the remaining 1,255 shares on February 14, 2019 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F6	Not applicable.